Age-related Macular Degeneration Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

1. Introduction

1.1. Research Methodology

1.2. Research Scope

1.2.1. Analysis by Company

1.2.2. Analysis by Phase

1.2.3. By Molecule Type

1.2.4. By region

2. Disease Overview

2.1.1. Introduction

2.1.2. Classification

2.1.3. Symptoms

2.1.4. Causes

2.1.5. Diagnoses

2.1.6. Treatment

2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

5.2.1. Phase of Development

5.2.1.1. Introduction

5.2.1.1.1. Drug Profiling

• Drug Name

• Generic Name

• Synonyms

• Company

• Collaborator

• Route of administration

• Target

• Mechanism of Action

• Technology

• Molecule type

• CAS Number

• Weight

• Chemical Formula

• IUPAC name

• ATC code

5.2.1.1.2. Strategic Developments

5.2.1.1.3. Clinical trials

5.2.1.1.4. Clinical trial results

5.2.1.1.5. Patents

5.2.1.1.6. Technology

5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)

5.3. By Molecule type

5.4. Analysis by Region

6. Company profiling

6.1. Alcon

6.1.1. Introduction

6.1.2. Financials

6.1.3. Products and Services

6.1.4. Recent Developments

6.1.5. SWOT

6.2. Astellas Pharma Inc

6.2.1. Introduction

6.2.2. Financials

6.2.3. Products and Services

6.2.4. Recent Developments

6.2.5. SWOT

6.3. RegenXBio Inc.

6.3.1. Introduction

6.3.2. Financials

6.3.3. Products and Services

6.3.4. Recent Developments

6.3.5. SWOT

6.4. Hoffmann-La Roche

6.4.1. Introduction

6.4.2. Financials

6.4.3. Products and Services

6.4.4. Recent Developments

6.4.5. SWOT

6.5. Alkahest, Inc.

6.5.1. Introduction

6.5.2. Financials

6.5.3. Products and Services

6.5.4. Recent Developments

6.5.5. SWOT

6.6. Allergan

6.6.1. Introduction

6.6.2. Financials

6.6.3. Products and Services

6.6.4. Recent Developments

6.6.5. SWOT

6.7. Opthea

6.7.1. Introduction

6.7.2. Financials

6.7.3. Products and Services

6.7.4. Recent Developments

6.7.5. SWOT

6.8. Belite Bio

6.8.1. Introduction

6.8.2. Financials

6.8.3. Products and Services

6.8.4. Recent Developments

6.8.5. SWOT

6.9. SciFluor Life Sciences, Inc.

6.9.1. Introduction

6.9.2. Financials

6.9.3. Products and Services

6.9.4. Recent Developments

6.9.5. SWOT

6.10. Biophytis

6.10.1. Introduction

6.10.2. Financials

6.10.3. Products and Services

6.10.4. Recent Developments

6.10.5. SWOT

List of Tables

List of Figures